Further analysis indicated that the pCR rate of HER2 enriched BC patients was highest (56.0%), followed by which was triple-negative BC (TNBC) (30.4%), both significantly higher than that of luminal B (16.7%) and luminal A (0.0%) BC patients (P = .001). This evidence concerns the gene ERBB2 and breast cancer.